Irvine Pharmaceutical Services, Inc. Enhances Staff, Prepares for Innovative Expansion

IRVINE, CA – Irvine Pharmaceutical Services, Inc., announced today that as part of its ongoing efforts to identify and meet current and future industry demands, the company has promoted Aryo Nikopour to Vice President of Scientific and Technical Services and added to its staff Chief Operating Officer Greg McParland. These changes come at an opportune time in the company’s growth as it gears up to launch its new subsidiary, Avrio Biopharmaceuticals, in January 2009.

After five years at Irvine and with a cumulative 20-plus years experience in the pharmaceutical industry, Aryo Nikopour offers to his new position a solid understanding and knowledge of the company as well as pharmaceutical development. His previous positions at highly reputable organizations such as PPD, Alpharma (Actavis), Solvay Pharmaceuticals and Solvay Animal Health, to name a few, has helped develop his expertise in a range of areas, including chromatographic method development and validation, Extractables/Leachables studies, and implementation of new technologies and capabilities such as Inhalation/Nasal, Biopharmaceutical and Structural Chemistry. Nikopour also has strong experience in scientific staff management, quality control, stability testing and regulatory requirements.

Greg McParland brings to Irvine more than 30 years of experience in the pharmaceutical and chemical industries. Prior to joining Irvine, McParland was Chief Executive Officer of Girindus America Inc., a member of Solvay Organics. There, McParland lead the R&D focused company through a major transition to become a commercial operation focused on small molecule and oligonucleotide active pharmaceutical ingredients. His additional leadership experience at companies such as Cambrex Corporation, Altergy Systems, NextPharma and Aerojet Fine Chemicals, in the areas of operations, sales and marketing, strategic planning, process optimization, and mergers and acquisitions, will be invaluable to both Irvine Pharmaceuticals and its new company, Avrio Biopharmaceuticals.

“We are looking forward to continued growth under the leadership of Aryo Nikopour and Greg McParland,” said Assad J. Kazeminy, CEO and Founder of Irvine Pharmaceutical Services. “I am confident they will lead us to even greater success as we expand and work to provide ever improving services to our clients.”

Since early 2007, Irvine Pharmaceutical Services, Inc., has experienced extensive growth, and has made significant upgrades in its lab equipment and infrastructure. You can meet Irvine staff and learn more about the company at the AAPS Annual Meeting, booth 1707.

Irvine Pharmaceutical Services, Inc. is a fully integrated services provider that works with pharmaceutical, biotechnology and medical device companies through all phases of research and development. Founded in 1988 and committed to expansion and services that benefit its clients’ priorities directly, Irvine is a fully cGMP compliant pharmaceutical product development and contract testing laboratory located in Irvine, CA. Irvine is able to support clients with analytical method development, stability testing, aseptic filling, HPLC method development, and pharmaceutical formulation. Visit www.irvinepharma.com or call (877) 445-6554. To learn more about Irvine's pharmaceutical manufacturing affiliate, Avrio Biopharmaceuticals, visit www.avriobiopharma.com.

10 Vanderbilt Irvine, California 92618 P: (877) 445-6554 F: (949) 951-4909 www.irvinepharma.com

10 Vanderbilt Irvine, California 92618 P: (877) 445-6554 F: (949) 951-4909 www.irvinepharma.com

Back to news